Clinical trial · Interventional
A Study of Adaptive Radiotherapy of Head-neck Cancer Using Daily Replanning and Optimization of the Treatment Plan.
DART-HN - Daily Adaptive Radiotherapy of Head-neck Cancer.
NCT07506902CI-TRIAL-00107100DART-HNrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Radiotherapy of head-neck cancer is associated with significant side effects. Using daily online adaptive radiotherapy to account for the changing anatomy, radiation to organs at risk can be lowered. We will investigate whether this is feasible and associated with a reduction in the risk of toxicity.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head & Neck Squamous Cell Carcinoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Daily online adaptive radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Daily online adaptive radiotherapy for head and neck cancer
- description
- Patients will undergo daily online adaptive radiotherapy for all fractions in the treatment course. The treatment plan will be re-optimised following recontouring on a daily basis using the Siemens-Varian Ethos Platform.
- interventionNames
- Radiation: Daily online adaptive radiotherapy
Primary outcomes (1)
- measure
- Risk of dysphagia and xerostomia six months post-treatment assesed by normal-tissue complication probability (NTCP) models
- timeFrame
- 6 months after treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically proven squamous cell carcinoma of the pharynx or larynx planned for primary radiotherapy with curative intent No current or earlier malignancies, which may influence treatment, evaluation or outcome of the head-neck cancer Informed consent as required by law The patient cannot participate in conflicting protocols Stage I-IV (excluding T1-T2N0 carcinoma of the glottic larynx) ECOG/WHO performance status 0-2 Exclusion Criteria: Patient with cancers of the glottic larynx (stage I/II), skull base, sino-nasal area and unknown primary tumor. Inability to attend full course of radiotherapy or follow-up visits in the outpatient clinic Distant metastasis Previous radiotherapy of the head and neck Previous surgery for the primary cancer with curative intent \-
References
Publications (0)
Data not yet available
No reference posted for this study.